Condition: β-thalassemia · Sponsor: Shanghai BDgene Co., Ltd.
This study will be intented to evaluate the safety, tolerability, and engraftment efficacy after myeloablative preconditioning and transplantation of autologous CD34+ hematopoietic stem cells transduced with a lentiviral vector encoding the human βA-T87Q-globin gene in patients with transfusion-dependent (TDT) β-thalassemia.
This description comes directly from the study's public registry record.
fujun Li · +86-19121311061 · fujun.li@bdgene.cn
Always discuss trial participation with your own doctor first.
| Sun Yat-sen Memorial Hospital | Guangzhou, Guandong, China | Recruiting |
| The First Affiliated Hospital of Guangxi Medical University | Nanning, Guangxi, China | Recruiting |
| Shanghai Ruijin Hospital, Shanghai Jiaotong University | Shanghai, Shanghai City, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06465550